Radioligand Therapy (RLT) Market to Surpass $10.91 Billion by 2035

Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC)…
posteditor
posteditor
Articles: 21727

Other News